Wei Ya Bin, Melas Philippe A, Villaescusa J Carlos, Liu Jia Jia, Xu Ning, Christiansen Søren Hofman, Elbrønd-Bek Heidi, Woldbye David Paul Drucker, Wegener Gregers, Mathé Aleksander A, Lavebratt Catharina
Department of Molecular Medicine and Surgery, Neurogenetics Unit (Drs Wei, Melas, Liu, and Lavebratt), Center for Molecular Medicine (Drs Wei, Melas, Villaescusa, Liu, Xu, and Lavebratt), Department of Clinical Neuroscience (Drs Melas and Mathé), Department of Molecular Biochemistry and Biophysics, Neurogenetics Unit (Dr Villaescusa), and Department of Medicine (Dr Xu), Karolinska Institutet, Stockholm, Sweden; Department of Neuroscience and Pharmacology, Laboratory for Neural Plasticity, University of Copenhagen, Denmark (Drs Christiansen, Elbrønd-Bek, and Woldbye); Translational Neuropsychiatry Unit, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark (Dr Wegener); Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom, South Africa (Dr Wegener).
Int J Neuropsychopharmacol. 2016 Dec 30;19(12). doi: 10.1093/ijnp/pyw069. Print 2016 Dec.
MicroRNAs (miRNAs) are small regulatory molecules that cause translational repression by base pairing with target mRNAs. Cumulative evidence suggests that changes in miRNA expression may in part underlie the pathophysiology and treatment of neuropsychiatric disorders, including major depressive disorder (MDD).
A miRNA expression assay that can simultaneously detect 423 rat miRNAs (miRBase v.17) was used to profile the prefrontal cortex (PFC) of a genetic rat model of MDD (the Flinders Sensitive Line [FSL]) and the controls, the Flinders Resistant Line (FRL). Gene expression data from the PFC of FSL/FRL animals (GEO accession no. GSE20388) were used to guide mRNA target selection. Luciferase reporter assays were used to verify miRNA targets in vitro.
We identified 23 miRNAs that were downregulated in the PFC of the FSL model compared with controls. Interestingly, one of the identified miRNAs (miR-101b) is highly conserved between rat and human and was recently found to be downregulated in the PFC of depressed suicide subjects. Using a combination of in silico and in vitro analyses, we found that miR-101b targets the neuronal glutamate transporter SLC1A1 (also known as EAAC1 or EAAT3). Accordingly, both mRNA and protein levels of SLC1A1 were found to be upregulated in the PFC of the FSL model.
Besides providing a list of novel miRNAs associated with depression-like states, this preclinical study replicated the human association of miR-101 with depression. In addition, since one of the targets of miR-101b appears to be a glutamate transporter, our preclinical data support the hypothesis of a glutamatergic dysregulation being implicated in the etiology of depression.
微小RNA(miRNA)是一类小的调节分子,通过与靶mRNA碱基配对导致翻译抑制。越来越多的证据表明,miRNA表达的变化可能在一定程度上是神经精神疾病(包括重度抑郁症,MDD)病理生理学和治疗的基础。
使用一种可同时检测423种大鼠miRNA(miRBase v.17)的miRNA表达检测方法,对MDD基因大鼠模型(弗林德斯敏感系,FSL)及其对照弗林德斯抗性系(FRL)的前额叶皮质(PFC)进行分析。利用FSL/FRL动物PFC的基因表达数据(GEO登录号GSE20388)指导mRNA靶标的选择。采用荧光素酶报告基因检测法在体外验证miRNA靶标。
我们鉴定出23种在FSL模型PFC中相对于对照下调的miRNA。有趣的是,其中一种鉴定出的miRNA(miR-101b)在大鼠和人类之间高度保守,最近发现其在抑郁自杀受试者的PFC中下调。通过计算机分析和体外分析相结合,我们发现miR-101b靶向神经元谷氨酸转运体SLC1A1(也称为EAAC1或EAAT3)。相应地,在FSL模型的PFC中发现SLC1A1的mRNA和蛋白质水平均上调。
除了提供与抑郁样状态相关的新miRNA列表外,这项临床前研究重现了miR-101与抑郁症的人类关联。此外,由于miR-101b的一个靶标似乎是谷氨酸转运体,我们的临床前数据支持谷氨酸能失调参与抑郁症病因的假说。